Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $17.00 target price on the stock.

A number of other equities analysts also recently weighed in on the company. William Blair began coverage on Immunic in a research report on Tuesday, March 25th. They set an “outperform” rating for the company. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.20.

Immunic Price Performance

IMUX stock opened at $0.90 on Thursday. The stock has a market capitalization of $81.15 million, a P/E ratio of -0.73 and a beta of 1.91. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11. The business has a 50-day moving average of $1.08 and a 200-day moving average of $1.16.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. acquired a new position in shares of Immunic during the 4th quarter worth about $37,000. Virtu Financial LLC acquired a new position in Immunic during the third quarter worth approximately $50,000. HB Wealth Management LLC bought a new stake in Immunic in the fourth quarter valued at approximately $81,000. Barclays PLC bought a new stake in Immunic in the fourth quarter valued at approximately $84,000. Finally, Jane Street Group LLC lifted its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.